Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history

Ratios

vs
industry
vs
history
P/E(ttm) 16.56
BBH's P/E(ttm) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BBH: 16.56 )
Ranked among companies with meaningful P/E(ttm) only.
BBH' s P/E(ttm) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 19.27
Current: 16.56
0
19.27
PE(NRI) 16.56
BBH's PE(NRI) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BBH: 16.56 )
Ranked among companies with meaningful PE(NRI) only.
BBH' s PE(NRI) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 19.27
Current: 16.56
0
19.27
P/B 4.20
BBH's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BBH: 4.20 )
Ranked among companies with meaningful P/B only.
BBH' s P/B Range Over the Past 10 Years
Min: 0  Med: 0 Max: 6.85
Current: 4.2
0
6.85

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.32
BBH's Dividend Yield is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BBH: 0.32 )
Ranked among companies with meaningful Dividend Yield only.
BBH' s Dividend Yield Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0.33
Current: 0.32
0
0.33
Yield on cost (5-Year) 0.32
BBH's Yield on cost (5-Year) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BBH: 0.32 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
BBH' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0.33
Current: 0.32
0
0.33

More Statistics

Short Percentage of Float0.00%
52-Week Range $95.56 - 128.29
Shares Outstanding (Mil)5,196,503.00
» More Articles for BBH

Headlines

Articles On GuruFocus.com
US Market Indexes Continue to Reach New Highs Dec 08 2016 
Buffett’s Yield on Cost for Coca-Cola Dec 09 2016 
Southern Company: Dividend Achiever Nearing a 5% Yield Dec 08 2016 
Royce Funds: What's the Outlook for U.S. Small-Caps? Dec 08 2016 
Big Insider Sell at Apple, Buy at Acushnet Dec 08 2016 
Mason Hawkins Adds to FedEx Dec 08 2016 
Altria Group Announces Quarterly Dividend Dec 08 2016 
Jim Chanos Adds to Starz Dec 08 2016 
Lam Research Increases Dividend by a Solid 50% Dec 08 2016 
Avoid Advanced Micro Devices Dec 08 2016 

More From Other Websites
Why Valbenazine Studies Seem Promising Dec 01 2016
Epclusa: Gilead Sciences’s Pan-Genotype Product Dec 01 2016
Trump Effect Elevated These Sector ETFs to Rank #1 Nov 30 2016
Understanding Allergan’s 3Q16 Revenue Stream Nov 29 2016
VanEck Announces Preliminary Year-End Distribution Estimates for VanEck Vectors Equity ETFs Nov 22 2016
5 Reasons to Buy 5 Low P/E Biotech ETFs Nov 14 2016
Generic-drug maker ETF could outperform biotech peers under Clinton Nov 08 2016
Biotech ETFs Slumping on Q3 Results Nov 08 2016
Healthcare ETFs in the Spotlight as Election Approaches Nov 07 2016
Treasury and Biotech: 2 ETFs to Watch on Outsized Volume Nov 07 2016
Exclusive: SunTrust Managing Director Shares Thoughts On Drug Pricing, Impact On Biotech Oct 20 2016
ETFs to Play as Biotech Juggles Election & Earnings Oct 17 2016
Bank and Biotech: 2 ETFs to Watch on Outsized Volume Oct 13 2016
Illumina's Pain Infects Biotech ETFs Oct 11 2016
How Could Robo-Advisors Change Investing? Oct 05 2016
Innovation In Focus For European ETFs Oct 05 2016
VanEck to Ring The Nasdaq Stock Market Opening Bell Sep 12 2016
Politic-proofing your portfolio: Pro Sep 09 2016
Clinton's Proposal To Combat Drug Price Hikes Sep 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK